Revista Clínica Española (English Edition) Revista Clínica Española (English Edition)
Clinical assessment and treatment of diabetes in patients with chronic kidney disease
Evaluación clínica y tratamiento de la diabetes en pacientes con enfermedad renal crónica
J. Carretero Gómez, , J.C. Arévalo Lorido
Servicio de Medicina Interna, Hospital Comarcal de Zafra, Badajoz, Spain
Received 04 March 2018, Accepted 19 March 2018

Diabetes mellitus type 2 is the main cause of chronic kidney disease. Patients with this disease have higher morbidity and mortality and risk of hypoglycaemia than those without this disease. In 2010, type 2 diabetes was the reason for starting renal replacement therapy in 24.7% of patients. The prevalence of microalbuminuria, proteinuria and a reduced glomerular filtration rate is 36%, 8% and 22%, respectively. The presence of albuminuria is a predictor of chronic kidney disease. Diabetic kidney disease, previously known as diabetic nephropathy, refers to kidney disease caused by diabetes. Renal hyperfiltration is a marker of intraglomerular hypertension and a risk factor for onset and progression. The new antidiabetic drugs, mainly dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter inhibitors and glucagon-like peptide-1 agonists, have been shown to prevent or slow the progression of kidney disease.


La diabetes mellitus tipo2 es la principal causa de enfermedad renal crónica. Estos pacientes presentan mayor morbimortalidad y riesgo de hipoglucemias que el resto. En 2010, la diabetes tipo2 fue causa del inicio de terapia renal sustitutiva en el 24,7% de los pacientes. La prevalencia de microalbuminuria, proteinuria y disminución del filtrado glomerular es del 36, 8, y 22%, respectivamente. La presencia de albuminuria es un factor predictivo de enfermedad renal crónica. La enfermedad renal diabética, previamente conocida como nefropatía diabética, hace referencia a la enfermedad renal causada por la diabetes. La hiperfiltración renal es marcador de hipertensión intraglomerular y factor de riesgo tanto de inicio como de progresión. Los nuevos antidiabéticos, fundamentalmente los inhibidores del enzima dipeptidil peptidasa-4, los inhibidores del cotransportador de sodio/glucosa y los agonistas del péptido similar al glucagón tipo1, han demostrado prevenir o enlentecer la progresión de la enfermedad renal.

Diabetes, Chronic kidney disease, Diabetic nephropathy, Diabetic kidney disease, SGLT2-i, GLP-1RA, DPP4-i
Palabras clave
Diabetes, Enfermedad renal crónica, Nefropatía diabética, Enfermedad renal del diabético, iSGLT2, arGLP1, iDPP4


To access the full text of the publication Revista Clínica Española (English Edition) you need to be a subscriber or member of the Sociedad Española de Medicina Interna.

  • If you are a member of the Sociedad Española de Medicina Interna::
    1.- You must go to the following address
    2.- Authenticate as a member of the SEMI. You must use your login details
    3.- Access to the contents of Revista Clínica Española

  • If you are a subscriber:
    Can you recover your data in the "I Forgot my Password" button on the right sidebar of this website.

Cookies Policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.